- Home
- DSGN vs CATX Comparison
DSGN vs CATX Comparison
Compare DSGN & CATX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSGN
- CATX
- Stock Information
- Founded
- DSGN 2017
- CATX 1983
- Country
- DSGN United States
- CATX United States
- Employees
- DSGN N/A
- CATX N/A
- Industry
- DSGN Biotechnology: Pharmaceutical Preparations
- CATX Medical/Dental Instruments
- Sector
- DSGN Health Care
- CATX Health Care
- Exchange
- DSGN Nasdaq
- CATX Nasdaq
- Market Cap
- DSGN 224.8M
- CATX 182.9M
- IPO Year
- DSGN 2021
- CATX N/A
- Fundamental
- Price
- DSGN $3.91
- CATX $2.43
- Analyst Decision
- DSGN Hold
- CATX Strong Buy
- Analyst Count
- DSGN 1
- CATX 9
- Target Price
- DSGN $4.00
- CATX $12.63
- AVG Volume (30 Days)
- DSGN 91.9K
- CATX 749.8K
- Earning Date
- DSGN 05-07-2025
- CATX 05-12-2025
- Dividend Yield
- DSGN N/A
- CATX N/A
- EPS Growth
- DSGN N/A
- CATX N/A
- EPS
- DSGN N/A
- CATX N/A
- Revenue
- DSGN N/A
- CATX $1,471,000.00
- Revenue This Year
- DSGN N/A
- CATX N/A
- Revenue Next Year
- DSGN N/A
- CATX N/A
- P/E Ratio
- DSGN N/A
- CATX N/A
- Revenue Growth
- DSGN N/A
- CATX N/A
- 52 Week Low
- DSGN $2.60
- CATX $1.60
- 52 Week High
- DSGN $7.77
- CATX $16.55
- Technical
- Relative Strength Index (RSI)
- DSGN 53.86
- CATX 53.99
- Support Level
- DSGN $3.67
- CATX $2.53
- Resistance Level
- DSGN $4.13
- CATX $2.77
- Average True Range (ATR)
- DSGN 0.30
- CATX 0.28
- MACD
- DSGN 0.05
- CATX 0.00
- Stochastic Oscillator
- DSGN 85.78
- CATX 58.93
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
About CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.